Belpointe Asset Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Belpointe Asset Management’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-101	Closed	-$2.42K	–	3555
2023 Q1	$2.42K	Hold	101	–	–	﹤0.01%	3260
2022 Q4	$1.72K	Buy	+101	New	+$1.63K	﹤0.01%	3309

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Belpointe Asset Management's CALT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2023, closing a stake of 101 shares — an estimated $2.42K sold.

Belpointe Asset Management first reported a position in CALT in Q4 2022 and held it in 2 quarters. The position peaked at $2.42K in Q1 2023. 16 funds tracked by Wall St. Rank hold CALT as of Q2 2023.

Belpointe Asset Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 101 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2023, an estimated $2.42K.
Belpointe Asset Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $2.42K in Q1 2023.
16 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.